Table 2.

Self‐reported ability

Self‐reported ability	Physicians directly involved in care of people with hemophilia (%)	Other respondents (%)
Ability to explain the science of AAV‐mediated liver‐directed gene therapy for hemophilia to a colleague (n = 177)
1—I’ve never heard of gene therapy	3	3
2—I do not have a clear understanding of how gene therapy works	6	6
3—I’ve learned about gene therapy, but still don’t think that I could explain it well to someone else	26	41
4—I know enough about gene therapy to feel comfortable educating colleagues, patients, and caregivers	54	40
5—I consider myself an expert	11	10
Ability to answer patient questions about gene therapy for hemophilia based on clinical trial results to date (n = 143)
1—I would not be able to answer questions about clinical trials of gene therapy for hemophilia	2	7
2—I have read about some of the studies, but would not feel very comfortable answering questions	11	24
3—I could answer a few basic questions about the studies	27	28
4—I feel comfortable answering questions about clinical trial results in gene therapy	50	30
5—I consider myself an expert	10	11
Ability to describe how gene therapy may impact an individual’s current treatment for hemophilia (n = 143)
1—I am not able to describe how gene therapy may impact an individual’s current treatment	1	9
2—I have a limited understanding of how gene therapy may impact current treatment practice for patients	16	22
3—I am able to explain how gene therapy may impact current treatment practice for patients	35	21
4—I am very comfortable with my ability to explain to my patients and colleagues how gene therapy may impact current treatment practice	38	35
5—I consider myself an expert	10	13

Abbreviation: AAV, adeno‐associated viral.